07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

Flucelvax Quadrivalent regulatory update

FDA approved Flucelvax Quadrivalent from CSL’s Seqirus unit to prevent infection from the 2 strains of influenza subtypes A and 2 strains of influenza type B contained in the vaccine in people ages >=4. Seqirus...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Company News

Novartis A infectious news

Novartis said FDA licensed the pharma’s manufacturing facility in Holly Springs, N.C., to produce cell-culture influenza vaccines. Novartis said that the facility will produce seasonal and pre-pandemic influenza vaccines, including the company’s seasonal influenza vaccine,...
08:00 , Jan 7, 2013 |  BioCentury  |  Finance

4Q Stock Wrap-Up: Go big or go home

Large cap biotechs were the only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26% gain on the year. Small caps brought up the rear in 4Q, but...
08:00 , Dec 3, 2012 |  BC Week In Review  |  Clinical News

Flucelvax regulatory update

FDA approved seasonal influenza vaccine Flucelvax from Novartis to prevent influenza subtypes A and type B in adults. Flucelvax is the first seasonal influenza vaccine approved in the U.S. that is manufactured using cell cultures...
01:31 , Nov 21, 2012 |  BC Extra  |  Company News

FDA approves Novartis' Flucelvax

FDA approved seasonal influenza vaccine Flucelvax from Novartis AG (NYSE:NVS; SIX:NOVN) to prevent influenza subtypes A and type B in adults. Flucelvax is the first seasonal influenza vaccine approved in the U.S. that is manufactured...